"Peptide Stable isotope–labeled internal standard peptide (Q 7 and K 15 reciprocally cross-linked dimer of LTIGEGQQHHL*GGAKQAGDV, where L* represents 13 C 6 , 15 N 1 -labeled leucine) was synthesized and analyzed for purity and amino acid content (CPC Scientific)"
Abstract
D-dimer is a product of the coagulation cascade and is associated with venous thromboembolism, disseminated intravascular coagulation, and additional clinical conditions. Despite its importance, D-dimer measurement has limited clinical utility due in part to the lack of reliable assays. The difficulty in developing an immunoassay that is specific for D-dimer arises from the inherent heterogeneity in its structure. In this report, we describe a highly specific method for the quantification of D-dimer level in human plasma. In our method, the reciprocally cross-linked peptide resulting from factor XIIIa-catalyzed dimerization of fibrin γ chains was selected to represent the D-dimer antigen. Using an antipeptide antibody, we enriched the cross-linked peptide from trypsin-digested plasma prior to quantitative analysis with liquid chromatography-tandem mass spectrometry (LC-MS/MS). The assay has a quantitative range of 500 pmol/L to 100 nmol/L in human plasma. In further characterization of the assay, we found that it exhibited good correlation with fibrinolytic activity in human donors and with thrombin generation and clot strength in an in vitro thromboelastography assay. These observations thus establish the biological relevance of the assay and suggest it may be a valuable biomarker in characterization and treatment of blood coagulation disorders.
SOCIAL MEDIA
Connect with us and stay updated by following our social media channels.
Latest Briefings from our Knowledge Center
Press Releases, Industry News, Articles, and Technical Content
CPC Scientific had a fantastic time connecting with partners this year at DCAT Week 2026. See our standout highlights from New York, featuring generic API scale-up, the 98th DCAT Annual Dinner, and more...
Catch CPC Scientific's key highlights from NextGen Biomed 2026, where we showcased how our advanced process design is accelerating production timelines and cost efficiency for greener TIDES manufacturing at scale...
Delivery of polypeptides in multi-kilogram quantities within commercially competitive timelines is extremely challenging, especially when coupled with a desire to minimize environmental and economic impact. This case study explores how CPC Scientific’s advanced process improvements and efficiencies within solid-phase peptide synthesis (SPPS) have enabled multi-kilogram delivery of a pharmaceutically-relevant decapeptide within a challenging timescale, driving sustainable and cost-saving production for the client.
As 2025 draws to a close, we want to extend our heartfelt thanks to our partners and colleagues around the world! Your trust and collaboration enabled CPC Scientific to make meaningful progress across our CDMO thought leadership, operational scale, and global business milestones this year. Explore featured highlights and resources from the year to see how our people, partners, and platforms drove innovation and impact throughout 2025.
President Theresa Cheng spoke to PhD students at Weill Cornell Graduate School, sharing industry insights and exploring how academic research today can translate into tomorrow’s cutting-edge healthcare leadership.
Our team has developed an innovative DMF recycling strategy that substantially reduces solvent consumption during solid-phase peptide synthesis. Minimizing use of DMF, a major environmental and cost contributor in peptide manufacturing, has improved process sustainability and cost efficiency. This method neatly demonstrates how targeted green chemistry practices can be successfully integrated into large-scale SPPS, supporting more environmentally responsible and economically viable peptide production.
CPC Scientific’s Rocklin facility is undergoing a major expansion to establish a 41,000 sq ft Center of Excellence for U.S.-based peptide API manufacturing. Construction is now underway—more updates coming soon.
From Nusinersen to Inclisiran, oligonucleotide APIs are rapidly reshaping modern drug development. Explore the role of oligonucleotide CDMOs in enabling analytical innovation and scalable, compliant manufacturing across the RNA therapeutic frontier.
Peptide and oligonucleotide APIs are driving a new generation of pharmaceutical drug development. Learn more about the API manufacturing process and why it matters to partner with a specialized peptide and oligonucleotide CDMO.